Jennifer Jarrett - 30 Mar 2026 Form 4 Insider Report for Damora Therapeutics, Inc. (DMRA)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: DMRA
Reported as of: 30 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 17:30:23 UTC
Prior SEC filing: 06 Feb 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Garrett Winslow, attorney-in-fact

Key filing fact

Jennifer Jarrett filed Form 4 for Damora Therapeutics, Inc. (DMRA) on 01 Apr 2026.

Key facts

This page summarizes Jennifer Jarrett's Form 4 filing for Damora Therapeutics, Inc. (DMRA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2026, 17:30.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001671311 Primary reporting owner

Jarrett Jennifer

Relationship: President and Chief Executive Officer, Director
Address: C/O DAMORA THERAPEUTICS, INC.,, 221 CRESCENT ST, BUILDING 23, SUITE 105, WALTHAM
Signature: /s/ Garrett Winslow, attorney-in-fact
Signature date: 01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMRA transaction

Common Stock

Award

Transaction value
Shares: +500,000
Change %
Price: $0.000000^*
Shares after: 500,000
Date: 30 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +1,500,000
Change %
Price: $0.000000^*
Shares after: 1,500,000
Date: 30 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500,000
Exercise price: $25.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F2

This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 30, 2027 and in equal monthly installments thereafter through March 30, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

President and Chief Executive Officer